Shenzhen Kangtai Biological Products Co., Ltd.
Announcement on Investment and Related Party Transaction
The Company and all members of the Board of Directors guarantee the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or major omissions.
I. Overview of Investment and Related Party Transaction
-
Shenzhen Kangtai Biological Products Co., Ltd. (hereinafter referred to as the "Company" or "Kangtai Bio") intends to acquire 51% of the equity (corresponding to a subscribed capital of RMB 51 million, with a paid-in capital of RMB 0) held by the original shareholders of Beijing Kunyuan Biotechnology Co., Ltd. (hereinafter referred to as "Beijing Kunyuan") for zero consideration, and will achieve consolidated accounting for this transaction (hereinafter referred to as the "Transaction"). The Company intends to sign the "Equity Transfer Agreement" related to this Transaction with the shareholders of Beijing Kunyuan, and the Board of Directors authorizes the Company's management to sign investment-related agreements and handle matters related to this Transaction.
-
The counterparties for this Transaction are Mr. Du Weimin, Mr. Liu Siyuan, Mr. Miao Xiang, Mr. Duan Bo, Mr. Nie Xiaoqi, and Ms. Ma Jianying. According to the "Rules Governing the Listing of Stocks on the ChiNext Market of the Shenzhen Stock Exchange," the aforementioned individuals are related natural persons to the Company, and this Transaction constitutes a related party transaction.
-
The tenth meeting of the eighth Board of Directors held on June 15, 2026, deliberated and approved the "Proposal on Investment and Related Party Transaction." Related directors Mr. Du Weimin, Mr. Miao Xiang, and Mr. Liu Jiankai abstained from voting, while the remaining 4 non-related directors unanimously approved it. The first special meeting of the eighth Board of Supervisors in 2026 had previously deliberated and approved this proposal. This proposal has also been deliberated and approved by the third meeting of the eighth Board of Directors' Strategic Committee in 2026, in compliance with the "Rules Governing the Listing of Stocks on the ChiNext Market of the Shenzhen Stock Exchange" and other relevant regulations.
-
This Transaction falls within the scope of the Board of Directors' approval authority and does not require submission to the Company's shareholders' meeting for deliberation. It has not reached the threshold for a major asset restructuring as stipulated in the "Measures for the Administration of Major Asset Restructuring of Listed Companies" and does not constitute a major asset restructuring. It does not require approval from relevant authorities.
II. Information on Transaction Counterparties (Related Parties)
- Du Weimin
Mr. Du Weimin, a Chinese national, residing in Beijing's Daxing District ***********, is the controlling shareholder, actual controller, director, and chairman of the Company. He is a related party to the Company and is not a dishonest judgment debtor.
- Miao Xiang
Mr. Miao Xiang, a Chinese national, residing in Shenzhen, Guangdong Province ***********, is a director and president of the Company. He is a related party to the Company and is not a dishonest judgment debtor.
- Liu Siyuan
Mr. Liu Siyuan, a Chinese national, residing in Beijing's Daxing District ***********, is a close relative of Mr. Liu Jiankai, a director and vice president of the Company. He is a related party to the Company and is not a dishonest judgment debtor.
- Duan Bo
Mr. Duan Bo, a Chinese national, residing in Ji'an City, Jiangxi Province ***********, is a close relative of Mr. Du Weimin, the controlling shareholder, actual controller, and chairman of the Company. He is a related party to the Company and is not a dishonest judgment debtor.
- Nie Xiaoqi
Mr. Nie Xiaoqi, a Chinese national, residing in Beijing's Daxing District ***********, is a vice president of the Company. He is a related party to the Company and is not a dishonest judgment debtor.